PIRCHE Partners with Cytopar to Bring Epitope-Level Precision to Virtual Crossmatch Workflows

GRÜNWALD, BAVARIA, GERMANY, May 12, 2025 PIRCHE AG, a Berlin-based leader in molecular epitope matching for transplantation, and Cytopar LLC, a U.S.-based provider of intelligent software solutions for HLA and clinical laboratories, have announced a strategic partnership to integrate PIRCHE T2 (PIRCHE-II) and PIRCHE B (Snow) epitope mismatch scores into Cytopar’s virtual crossmatch platform. This collaboration enables transplant centers and laboratories to access advanced molecular-level immunologic insights directly within existing lab workflows, helping teams make faster, more informed decisions in donor selection and risk assessment.

PIRCHE’s patented epitope matching algorithms provide more granular data on patient immune dynamics, supporting a range of decisions throughout the transplant timeline—from donor selection and risk stratification to immunosuppression management. Cytopar, meanwhile, has developed a breakthrough virtual crossmatch solution that integrates seamlessly with existing HLA laboratory information systems, streamlining workflows and reducing the risk of manual error.

"At Cytopar, we’re focused on making laboratory workflows smarter and more intuitive," said Dr. Jorge Moraleda, Cytopar’s Founder & Chief Executive Officer. "By integratingPIRCHE’s molecular epitope matching into our virtual crossmatch platform, we’re equipping labs with deeper immunologic insight at the exact moment it’s needed—supporting faster, more confident transplant decisions."

Christopher McCloskey, ExecutiveVice President of Transplant Medicine at PIRCHE, added, "Epitope-level matching is becoming an essential tool for risk assessment and donor selection.Our partnership with Cytopar ensures that PIRCHE’s advanced algorithms are now directly accessible within clinical workflows, enabling transplant programs toapply data-driven risk profiling without additional operational burden."

About PIRCHE AG

PIRCHE is a leading provider of digital molecular diagnostic solutions for transplant medicine. The company’s mission is to improve the lives of transplant patients by providing innovative and accurate diagnostic tools. PIRCHE is headquartered in Grünwald, near Munich, and has offices in Boston, Berlin, and Utrecht. To learn more about PIRCHE’s breakthrough technology and how it can support better patient outcomes, visit PIRCHE.com.

.

‍